Memphasys tech shows advantages in small-scale sperm preparation trial
ASX-listed reproductive biotechnology company Memphasys has announced results showing “clear benefits” of its Felix technology versus two widely used technologies in a Japanese trial, with results from a larger-scale trial expected to be shared in late-2024. According to an ASX statement from the company on Monday, the Felix System (pictured) outperformed a sperm preparation method…